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Abstract 
Background:  Glucocorticoid‑induced leucine zipper (GILZ) is a potent anti‑inflammatory protein involved in neutro‑
phil apoptosis and the resolution of inflammation. Given the numerous pathophysiologic roles of neutrophils in the 
acute respiratory distress syndrome (ARDS), we postulated that neutrophil GILZ expression might be induced during 
ARDS, to modulate the inflammatory process and participate in lung repair.
Methods:  This single‑center, prospective, observational cohort study took place in the surgical intensive care unit of 
Bichat Hospital (Paris, France) and involved 17 ARDS patients meeting the Berlin criteria at inclusion, and 14 venti‑
lated controls without ARDS. Serial blood samples were obtained every 2 days until extubation or death (from 1 to 9 
samples per patient). GILZ protein and gene expression was quantified in blood neutrophils, along with markers of 
inflammation (CRP, extracellular DNA) or its resolution (Annexin A1).
Results: Neutrophil GILZ expression was detected at the transcriptional and/or translational level in 9/17 ARDS 
patients (in particular 7/10 severe ARDS) and in 2/14 ventilated controls. The highest mRNA levels were observed in 
the most severely ill patients (p < 0.028). GILZ was expressed in about ¾ of the corticosteroid‑treated patients and its 
expression could also occur independently of corticosteroids, suggesting that inflammatory signals may also induce 
neutrophil GILZ expression in vivo.
Conclusions:  In this pilot study, we show for the first time that blood neutrophils from patients with ARDS can 
express GILZ, in keeping with an anti‑inflammatory and regulatory endogenous role of GILZ in humans. Contrary to 
some markers of inflammation or its resolution, the levels of gilz gene expression were related to ARDS severity.
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Background
The acute respiratory distress syndrome (ARDS) is one 
of the most severe forms of acute respiratory failure [1] 
characterized by diffuse alveolar damage. High alveo-
lar concentrations of inflammatory mediators trigger 
excessive neutrophil influx and activation, leading to 
the release of reactive oxygen species (ROS), proteases, 
cytokines and neutrophil extracellular traps (NETs), all 
of which can contribute to alveolar injury [2]. Both cir-
culating and alveolar neutrophils exhibit delayed apopto-
sis in this setting, and this is associated with lung injury, 
impaired resolution of inflammation, clinical severity, 
and poor outcome [3, 4].
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Despite significant research, ARDS management still 
consists mainly of supportive care, based on optimized 
ventilation and extracorporeal membrane oxygenation 
(ECMO) [5]. New therapeutic strategies based on modu-
lation of inflammation, using mesenchymal stromal cells, 
miRNA, or regulatory T cells, have recently been pro-
posed [6–8]. Steroids have controversial effects when used 
early during the course of ARDS [9], but have been shown 
to reduce fibroblast proliferation and cytokine release 
when used in the late phase, thereby improving recovery 
[10]. Another effect of steroid therapy might be the induc-
tion of glucocorticoid-induced leucine zipper (GILZ).
GILZ is an immunomodulatory protein belonging to 
the transforming growth factor-β-stimulating clone 22 
domain (TSC-22D) family [11]. GILZ can also be induced 
in vitro by TGF-β and IL-10 [12], and has been detected 
both in a murine model of arthritis and in the joints of 
patients with rheumatoid arthritis [13]. These recent 
in vivo findings suggest that, in some inflammatory con-
ditions, GILZ may be induced independent from exog-
enous corticosteroid administration.
In vitro, GILZ regulates major inflammatory signal 
transduction pathways such as activator protein 1 (AP-
1), nuclear factor-kappa B (NF-кB), and forkhead box O 
(FOXO) [11, 14]. GILZ has also been implicated in the 
control of apoptosis and cell survival in various cell types 
[11, 15, 16]. We recently showed that GILZ expression 
by human neutrophils in vitro promotes their apoptosis 
[17]. These results were confirmed in vivo by Vago et al. 
[18] who found that preventive or therapeutic adminis-
tration of the cell-permeable TAT-GILZ fusion protein 
improved resolution in a mouse model of LPS-induced 
pleurisy. GILZ thus appears to be an important regula-
tor of neutrophil apoptosis in vitro and in vivo, contrib-
uting to the resolution of inflammation. The mechanisms 
of GILZ action involve the well-described anti-inflam-
matory and pro-resolving factor Annexin A1 [18, 19]. 
Indeed, endogenous Annexin A1 induces neutrophils 
to undergo apoptosis and promotes their efferocytosis 
by macrophages, as demonstrated in  vivo in the mouse 
model of LPS-induced pleurisy [20].
We postulated that neutrophil GILZ expression might 
be induced during ARDS, to modulate the inflammatory 
process and participate in lung repair. The aim of this 
pilot study was thus to analyze the kinetics of blood neu-
trophil GILZ expression at the protein and mRNA levels 
in ventilated septic patients with and without ARDS, and 
treated or not by corticosteroids. The levels of gilz mRNA 
were then analyzed according to ARDS severity, in com-
parison with some markers of inflammation (circulating 
CRP and extracellular DNA) or its resolution (Annexin 
A1), to assess whether GILZ might be included in a new 
biological signature of ARDS severity.
Methods
Study setting and population
We conducted a single-center, prospective, pilot, 
observational cohort study of ARDS patients hospital-
ized in the intensive care unit (ICU) of Bichat Hospi-
tal (Paris, France) from January 2012 to March 2013. 
Patients with HIV infection, hepatitis, transplanta-
tion, end-stage cancer, age below 18 years, or ongoing 
pregnancy were excluded. The protocol was approved 
by the ethics committee of Paris-Bichat Hospital 
(CEERB, comité d’évaluation de l’éthique des projets 
de recherche biomédicale, No. 12-028, Paris, France), 
and informed consent was obtained from the patients’ 
legally authorized relatives. Patients mechanically ven-
tilated with a positive end-expiratory pressure above 
5  cm H2O were prospectively included and classified 
into two groups: patients with ARDS (n  =  17) and 
ARDS-free ventilated controls (n  =  14), according 
to the Berlin definition of ARDS (acute hypoxemia, 
ratio of partial pressure of arterial oxygen (PaO2)/
fraction of inspired oxygen (FiO2) of 300  mmHg or 
less, and bilateral infiltrates on chest X-ray) [1]. The 
control group consisted mainly of postoperative care 
or trauma patients receiving mechanical ventilation 
for respiratory failure without ARDS criteria. Blood 
samples were obtained prospectively during routine 
care, the first within 24  h after ARDS diagnosis or 
ICU hospitalization and then every 2  days until extu-
bation or death. The following clinical parameters 
were collected at inclusion: age, sex, reason for ICU 
admission, CRP plasma level (Dimension Vista®1500, 
Siemens Healthcare diagnostics, n  <  6  mg/L), ARDS 
etiology, Simplified Acute Physiology Score II (SAPS 
II) [21], Sequential Organ Failure Assessment Score 
(SOFA) [22], Lung Injury Score (LIS) [23], ventila-
tion parameters (PaO2/FiO2 ratio), and use of extra-
corporeal membrane oxygenation (ECMO) and other 
treatments (steroids and vasoactive agents) as recom-
mended by the standard of care of patients with ARDS 
[24]. ECMO was used as rescue therapy if hypoxemia 
persisted despite optimal mechanical ventilation, neu-
romuscular blocking agent administration, and nitric 
oxide inhalation. Intravenous hydrocortisone hemisuc-
cinate (200 mg/day) was administered in case of severe 
septic shock with an inadequate response to vascular 
filling and cardiovascular treatment [25]. Vital status 
was recorded 28 days after inclusion.
Blood neutrophil isolation
Neutrophils were isolated immediately after blood sam-
pling by sedimentation on a separating medium contain-
ing 5% Dextran T500® (Pharmacia, Uppsala, Sweden) 
in 0.9% saline and centrifugation on a Ficoll gradient 
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(Eurobio, Les Ulis, France) as previously described [26, 
27]. Erythrocytes were removed by hypotonic lysis.
Immunoblotting of neutrophil‑derived GILZ protein
Neutrophils were lysed in cold Laemmli buffer (5% Tris 
pH 6.8 1.25  M, 10% glycerol, 10% SDS, 1  mM PMSF, 
1  mM Na3VO4, 25  mM β-glycerophosphate, 10  µg/ml 
aprotinin, 10  µg/ml leupeptin, and 10  µg/ml pepstatin), 
then boiled, and sonicated. The total protein concentra-
tion was measured by bicinchoninic acid assay, and equal 
amounts of denatured protein were loaded on 12% SDS-
PAGE gels and transferred to PVDF membranes. The 
membranes were incubated with a polyclonal rabbit anti-
body raised against human GILZ that was developed in 
our laboratory [15], stripped, and reprobed with an anti-
body against p38 MAP Kinase (Cell signaling, Danvers, 
USA, ref 9212) as a loading control.
Real‑time PCR analysis of the neutrophil gilz and annexin 
A1 genes
Neutrophils were lysed in RLT buffer (Qiagen, Courta-
boeuf, France) and stored after homogenization of 
the lysate through a QIAshreder column. Total RNA 
was isolated with the Qiagen Mini Plus Kit accord-
ing to the manufacturer’s protocol. RNA integrity was 
evaluated by capillary electrophoresis using RNA 6000 
Nano chips and the Bioanalyzer 2100 (Agilent Tech-
nologies). Reverse transcription was carried out as pre-
viously described [28]. Real-time PCR analysis was 
performed using SYBR Green technology on a Biorad 
CFX96 system with Sso Fast EvaGreen Supermix (Bio-
Rad, Marnes la Coquette, France) and appropriate prim-
ers for gilz [5′-TCTGCTTGGAGGGGATGTGG-3′ and 
5′-ACTTGTGGGGATTCGGGAGC-3′] [29], gapdh 
[5′-CAGCCTCAAGATCATCAGC A-3′ and 5′-TGTG-
GTCATGAGTCCTTCCA-3′], b2m (beta-2-microglob-
ulin) [5′-ACCCCCACTGAAAAAGATGA-3′ and 
5′-ATCTTCAAACCTCCATGATG-3′], and annexin A1 
(Qiagen QuantiTect primer assay QT00078197), as pre-
viously described [28]. The cDNA was amplified with 
500-nM final concentrations of each primer, in duplicate 
10-µl reactions, by 45 two-step cycles (95  °C 5  s; 60  °C 
30  s). “No RT” controls were amplified on all genes to 
control for genomic DNA contamination, and melting 
curve analysis was performed to assess the purity of the 
PCR products. Serial dilutions of a pool of cDNA sam-
ples were used to construct linear standard curves, from 
which PCR efficiencies (E) were calculated for each gene. 
GeNorm in qBase Plus tool [29] was used to select b2m 
and gapdh as reference genes for normalization of mRNA 
expression results. The normalized relative expres-
sion of target genes in samples was determined using 
the ∆∆Cq method with correction for PCR efficiencies, 
where NRQ  =  ETarget−ΔCq Target/ERef−ΔCq Reference and 
∆Cq =  Cqsample −  Cqcalibrator [30, 31]. Final results were 
expressed as the n-fold differences in target gene expres-
sion in a given ARDS patient vs one arbitrarily chosen 
control patient.
Circulating extracellular DNA quantification
Circulating DNA was extracted from plasma by using 
the QiAmp Ultrasens Kit (Qiagen) and stored at −20 °C 
until use. Cell-free DNA was quantified by fluorimetry 
in the Quanti-iT™ Picogreen dsDNA assay (Molecular 
Probes, Eugene, USA) according to the manufacturer’s 
instructions. The fluorescence signal was recorded on 
a plate reader (TECAN Infinite® M200, Männedorf, 
Switzerland).
Statistical analysis
Demographic data were expressed as the median cor-
rected by the interquartile range (IQR). Fisher’s exact 
test or the Chi-square test was used to assess the com-
parability of the study cohort with the control group. 
Nonparametric variables were compared by using the 
Mann–Whitney U test or the Kruskal–Wallis test for 
multiple comparisons.
Neutrophil expression of gilz and annexin A1 mRNA 
and plasma levels of extracellular DNA and CRP were 
compared between mild/moderate ARDS patients, 
severe ARDS patients, and controls. A linear mixed-
effects regression model was used to take into account 
the repeated nature of the data and the different times of 
measurement, and to compensate for data attrition.
In the mixed-effects models, we considered the gilz 
mRNA expression logarithm in order to improve data 
normality. The 95% confidence interval and correspond-
ing (two-tailed) p value were estimated by boostrapping 
with 1000 replications. A p value < 0.05 was considered 
statistically significant.
We defined an arbitrary positivity threshold for gilz 
mRNA expression as the mean plus twice the standard 
deviation of the controls’ gilz mRNA levels in at least 
one of the first two serial samples; this value was 2.8 
arbitrary units. We used only the first two samples in 
order to compensate for data attrition, allowing us to 
analyze an equivalent number of data for each group. 
Consequently, a “gilz-positive” patient had a gilz 
expression level above the threshold in at least one of 
his/her first two samples. We then analyzed several fea-
tures of “gilz-positive” patients by using the Chi-square 
test.
All analyses were done using GraphPad software (San 
Diego, CA, USA) and R version 3.0.2 (R Foundation for 
Statistical Computing, Vienna, Austria) implemented in 
the lme4 package version 1.0-4.
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The sample size was not calculated in this pilot study 
because this is the first study to report the gilz expression 
levels in neutrophils from patients with ARDS, and no 
evidence could be referenced for statistical power analy-
sis. Instead, the sample size was determined by our previ-
ous experience.
Results
Characteristics of the patients
 A total of 17 ARDS patients and 14 controls were con-
secutively enrolled. Their main characteristics are shown 
in Table  1. The ARDS and controls had similar general 
severity scores (SAPS II and SOFA). The reasons for ICU 
admissions were similar (mainly sepsis, postoperative 
care, or trauma). The ARDS patients stayed longer in the 
ICU than the controls, allowing serial blood sampling for 
GILZ analysis.
The gilz gene is transiently expressed by blood neutrophils 
from ARDS patients, which depends on corticosteroids 
but not on vasoactive agent administration
Neutrophil gilz expression was transiently detected in 
several ARDS patients (9/17) but only in few controls 
(2/14). Figure  1a shows the time course of gilz mRNA 
expression in two representative controls and two rep-
resentative ARDS patients. Depending on the patients, 
1–9 mRNA samples could be obtained during the ICU 
stay and analyzed. Neutrophil gilz mRNA relative quan-
tity was significantly increased in patients with steroid 
therapy as compared with patients without corticoster-
oids (p < 0.05) (4.2 ±  6.7 and 1.7 ±  3.2 arbitrary units) 
(Fig.  1b), but was also evidenced in the absence of cor-
ticotherapy (Fig.  1a, b). Vasoactive agents were admin-
istered to 65% of the 31 patients; gilz expression was 
similar in patients who did and did not receive vasoactive 
agents (2.2 ± 4.3 and 2.6 ± 5.0 arbitrary units) (Fig. 1c).
GILZ protein is transiently expressed by blood neutrophils 
from ARDS patients
GILZ was detected in neutrophil homogenates from 7 
upon the 8 ARDS patients that could be studied (good 
quality protein samples for 47% of the ARDS patients) 
and was almost undetectable in the 6 controls studied 
(Fig. 2).
Depending on the patients, 1–5 protein samples could 
be obtained during the ICU stay and analyzed. GILZ pro-
tein was transiently expressed during ARDS, as described 
above for gilz gene expression (Fig. 2).
Neutrophil gilz mRNA levels are related to ARDS severity
We then wanted to compare neutrophil gilz mRNA lev-
els in controls, mild/moderate ARDS patients, and severe 
ARDS patients. We first analyzed the highest value of 
gilz expression for each patient and found that it tended 
to be higher in ARDS patients than in controls, particu-
larly when only severe ARDS patients were considered 
(Fig.  3). We then used a linear mixed-effects regression 
model to refine this comparison and to compensate for 
data attrition linked to differences in the numbers of 
serial samples analyzed for each patient (n = 1–9). This 
allowed us to calculate predicted gilz mRNA levels based 
on available measured values. As shown in Fig. 4a, pre-
dicted gilz mRNA levels did not differ between mild/
moderate ARDS patients and controls (p = 0.665). How-
ever, predicted gilz mRNA levels were higher in severe 
ARDS patients than in controls (p  =  0.035) and mild/
moderate ARDS patients (p = 0.028) (Fig. 4a). Although 
gilz mRNA expression appeared variable in time, no lin-
ear interaction or association with time was found. We 
then examined whether gilz expression was related to the 
PaO2/FiO2 ratio and found that the correlation between 
gilz expression and a PaO2/FiO2 below 100 was very close 
to statistical significance (p  =  0.054) (data not shown). 
Interestingly, gilz expression was significantly higher 
in ARDS patients receiving ECMO than in other ARDS 
patients (p < 0.005) (Fig. 4b). 
To evaluate GILZ as a possible new marker of ARDS 
severity, we used the same linear mixed-effects regres-
sion model to analyze three other parameters related to 
inflammation (CRP, extracellular DNA) or its regulation 
(Annexin A1). We found that predicted circulating CRP 
levels did not differ across the three patient groups (Fig. 5a) 
and that gilz gene expression did not correlate with CRP 
levels (data not shown). As extracellular DNA levels have 
been linked to organ injury in some forms of acute lung 
injury and sepsis, we measured extracellular DNA in the 
same samples and found no difference across the three 
groups of patients (Fig. 5b), confirming that this parameter 
is not specific for ARDS. Finally, we analyzed neutrophil-
derived Annexin A1, as this glucocorticoid-inducible pro-
resolving protein can cooperate with GILZ to dampen 
inflammation. We found that predicted annexin A1 mRNA 
levels did not differ across the three groups of patients 
(Fig. 5c), suggesting that annexin A1 regulation may occur 
at a different level than gilz regulation.
Together, these results show that GILZ can be 
expressed by neutrophils during the course of ARDS, at 
both the protein and gene level, and that its expression 
level is associated with clinical severity, more specifically 
than other markers of inflammation or its resolution.
Clinical definition of “gilz‑positive” ARDS patients
We then analyzed several features of “gilz-positive” 
patients (see above), including clinical parameters 
(ARDS, septic shock at inclusion, and pneumonia at 
inclusion [32]), treatment, and mortality. Using the 
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Chi-square test to assess whether or not two variables 
were independent, we found that neutrophil gilz gene 
expression was associated with ARDS (p < 0.05) but not 
with septic shock or pneumonia (Table 2). The percent-
age of “gilz-positive” patients was higher in the severe 
ARDS group (70%) than in the mild/moderate ARDS 
group (29%) and than in the ventilated controls (14%). 
Corticosteroid therapy might play a role in gilz induction 
as neutrophils from steroid-treated patients expressed 
gilz in 71% of cases (Table 2). However, these results also 
suggest that steroid therapy was not required for gilz 
expression and that other inducers could be active. This 
model also confirmed that neutrophil gilz expression 
was not linked to administration of vasoactive agents 
(Table 2). Finally, gilz positivity was not linked to day-28 
mortality among ARDS patients (Table 2).
Table 1 Characteristics of the patients
ARDS acute respiratory distress syndrome, LIS Lung Injury Score [23], SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiology Score II [21], 
ECMO Extracorporeal membrane oxygenation, CRP C-reactive protein, IQR interquartile range
p values: determined by Kruskal–Wallis test or Fisher’s exact test for continuous and categorical variables, respectively
a During the ICU stay
Patients Ventilated controls 
(n = 14)
Mild (n = 1) and moderate 
(n = 6) ARDS
Severe ARDS (n = 10) p value
Age (years, median ± IQR) 56 ± 19 52 ± 24 59 ± 6 0.82
Male/female (number) 9/5 6/1 7/3 0.78
Comorbidities
 Smoking (number, percentage) 4 (29%) 5 (71%) 2 (20%) 0.07
 Obstructive airway diseases (number, percent‑
age)
5 (36%) 5 (71%) 4 (40%) 0.27
 Cardiovascular disease (number, percentage) 1 (7%) 1 (14%) – 0.49
 Diabetes (number, percentage) 2 (14%) 1 (14%) – 0.45
 Malignancy (number, percentage) – 1 (14%) 1 (10%) 0.39
Reasons for ICU admission
 Sepsis (number, percentage) 7 (50%) 6 (86%) 8 (80%) 0.15
 Pneumonia (number, percentage) 5 (36%) 5 (71%) 5 (50%) 0.30
 Postoperative care (number, percentage) 11 (79%) 7 (100%) 9 (90%) 0.36
 Congestive heart failure (number, percentage) 2 (14%) 1 (14%) – 0.45
 Hemorrhagic shock (number, percentage) 1 (14%) 2 (29%) – 0.13
 Trauma (number, percentage) 4 (29%) 1 (14%) 3 (30%) 0.73
 SAPS II (median ± IQR) 39.0 ± 13.5 45.0 ±  21.0 43.5 ± 20.5 0.67
 SOFA at inclusion (median ± IQR) 6 ± 4 7 ± 2 7.5 ± 3.5 0.06
 CRP at inclusion (mg/L, median  ± IQR) 217 ± 325 211 ± 195 273 ± 313 0.80
 Number of samples per patient (range) 1–5 1–5 1–9 –
Cause of lung injury
 Pneumonia at inclusion (number, percentage) 5 (36%) 5 (71%) 8 (80%) 0.081
 Aspiration (number, percentage) 1 (7%) 2 (29%) 3 (30%) 0.29
 Septic shock at inclusion (number, percentage) 5 (36%) 6 (86%) 8 (80%) 0.043
 Extra pulmonary cause (number, percentage) – 3 (43%) 2 (20%) 0.038
 Steroid therapya (number, percentage) 1 (7%) 1 (14%) 5 (50%) 0.051
 Vasoactive agent therapya (number, percent‑
age)
7 (50%) 7 (100%) 6 (60%) 0.065
 Lung injury score at inclusion (median ± IQR) 0.67 ± 0.91 2.33 ± 0.66 3.00 ± 0.72 <0.0001
Respiratory variables
 Positive end‑expiratory pressure, cmH20 
(median ± IQR)
5 ± 0.5 8 ± 1 9 ± 2 0.001
 PaO2/FiO2 at inclusion mmHg (median ± IQR) 253 ± 85 210 ± 49 67 ± 29 <0.0001
 PaCO2 at inclusion mmHg (median ± IQR) 41 ± 5 43 ± 4 43 ± 4 0.72
 ECMOa (number, percentage) – – 6 (60%) 0.0004
 Mortality at day 28 (number, percentage) 4 (28%) 2 (29%) 6 (60%) 0.26
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Discussion
The main findings of this pilot study are that GILZ, a 
potent regulator of inflammation, can be induced in 
ARDS patients’ blood neutrophils, that its expression 
is transient, and that mRNA levels are related to ARDS 
severity. Therapeutic GILZ upregulation might thus con-
stitute a potential beneficial approach in ARDS.
During ARDS, lung edema and endothelial/epithelial 
cell damage promote the recruitment and activation of 
neutrophils in interstitial and bronchoalveolar spaces. 
The overwhelming inflammatory response associated 
with ARDS not only targets the lung but also causes 
persistent elevation of circulating protease and cytokine 
levels, and primed or hyperactivated neutrophil num-
bers, leading to extrapulmonary organ dysfunction [2, 
33]. The mechanisms that regulate this acute, severe 
inflammatory response are poorly understood. Neu-
trophils themselves might help to dampen this inflam-
mation, by releasing IL-1RA or TGF-β, by adopting an 
immunosuppressive phenotype (CD16bright CD62-Ldim) 
or by engaging in crosstalk with other immune cells [34, 
35]. Indeed, we have previously shown that neutrophil-
derived extracellular traps (NETs) can downregulate 
dendritic cell activation in vitro, thereby inducing Th2 T 
Fig. 1 a Kinetics of gilz mRNA expression in neutrophils from 2 representative controls and 2 representative ARDS patients. The number of serial 
blood samples obtained (every 2 days until extubation or death) is indicated (n = 2–9 per patient, depending on the patient). Some patients 
received hydrocortisone hemisuccinate (200 mg/day; steroid). Relative quantity of gilz mRNA was expressed as gilz expression level divided by the 
mean of gapdh and b2m levels. b Implication of corticoid therapy in gilz mRNA expression in all samples studied. Results are expressed as the rela‑
tive quantity of gilz mRNA (mean ± standard error of the mean). *p < 0.05, Mann–Whitney test. c Implication of vasoactive agent administration in 
all samples studied. Results are expressed as the relative quantity of gilz mRNA (mean ± standard error of the mean). ARDS acute respiratory distress 
syndrome, GILZ glucocorticoid‑induced leucine zipper
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lymphocyte polarization [27]. Moreover, a new neutro-
phil-related gene signature has been described in patients 
with early sepsis-induced ARDS, based on two anti-
inflammatory genes: OLFM4 (encoding olfactomedin 4) 
and LCN2 (encoding lipocalin 2) [36]. The main objective 
of the present study was to determine whether GILZ, an 
anti-inflammatory protein that we recently found to be 
expressed by human neutrophils in particular stimula-
tory conditions in vitro [17], is modulated during ARDS.
We show for the first time that gilz is expressed by 
blood neutrophils of most severe ARDS patients but 
in only a minority of mild/moderate ARDS patients 
or ARDS-free ventilated controls. Interestingly, GILZ 
expression during ARDS was transient. The very short 
half-life of gilz transcripts, of around 2 h in murine lym-
phocytes [16] and macrophages [37], would explain, at 
least in part, this transient expression. Our study pro-
vides new insights into the neutrophil-related events, 
adding a new gene in the recently described signature 
[36].
Neutrophil gilz mRNA levels were related to ARDS 
severity, being significantly higher in severe ARDS 
patients (reaching levels of 7–9 times the threshold value) 
than in mild/moderate ARDS patients and in ventilated 
controls. Moreover, patients receiving ECMO had higher 
gilz expression than patients without ECMO. This res-
cue therapy is used in severe ARDS when conventional 
mechanical ventilation fails [5, 38]. As ECMO has been 
shown to have pro-inflammatory effects in vivo [39, 40], 
it is conceivable that GILZ induction was aimed at com-
pensating for these effects.
In order to better document the clinical relevance of 
gilz expression in this setting, we used the linear mixed-
effects regression model to compare circulating levels of 
two classical markers of inflammation (CRP and extra-
cellular DNA) in the three patient groups. CRP levels 
did not differ across the three groups and did not corre-
late with the neutrophil gilz expression level, suggesting 
that GILZ expression is not only induced by inflamma-
tory signals. Extracellular DNA levels are a marker of 
NET release. NETs are decondensed DNA fibers that 
bear histones and several proteins from the granular and 
Fig. 2 Kinetics of GILZ protein expression in ARDS patients and controls. Representative serial Western blot data for 8 ARDS patients (A to H) and 6 
controls (I to N) performed every 2 days. p38 MAPK expression served as control. A1 sample 1 of patient A, A2 sample 2 of patient A
Fig. 3 gilz mRNA expression in the neutrophils of ARDS and 
controls (highest point of gilz expression for each patient). Results 
are expressed as the mean ± standard error of the mean. Relative 
quantity of gilz mRNA was expressed as gilz expression level divided 
by the mean of gapdh and b2m levels. ARDS acute respiratory distress 
syndrome, GILZ glucocorticoid‑induced leucine zipper
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cytoplasmic compartments, which can induce lung dam-
age [41]. We found that circulating extracellular DNA 
levels were similarly elevated in the three patient groups, 
independently of clinical severity. This concurs with the 
results of Yildiz et  al. [42] who found that mechanical 
ventilation induced netosis in an animal model of sepsis, 
but that netosis had no major pathogenic effect. How-
ever, netosis intensity has been linked to severity in two 
models of sterile ARDS: acid-aspiration-induced ARDS 
[43] and transfusion-related acute lung injury [44]. Gilz 
expression might thus be a more specific marker of ARDS 
severity than other markers such as CRP and NETs.
The stimuli leading to neutrophil gilz expression in vivo 
are probably multiple in ARDS. Even if steroid therapy 
did not appear to be a prerequisite for gilz expression, 
it was observed in almost ¾ of corticosteroid-treated 
patients. We found a near-significant negative correla-
tion between gilz levels and the PaO2/FiO2 ratio, sug-
gesting that hypoxia could play a role. Consistent with 
our results, GILZ expression was recently reported to 
be induced by hypoxia in  vitro, in both murine mac-
rophages [45] and human epithelial cells [46]. The pres-
ence of areas of hypoxia being a prominent feature of 
inflamed tissues, GILZ expression could be induced not 
Fig. 4 gilz gene expression in relation to ARDS severity. a gilz expression levels predicted by a linear mixed model. Controls (full line), mild/moder‑
ate ARDS patients (small dotted line), and severe ARDS patients (large dotted line) are represented. For each prediction, the confidence interval is 
represented by the gray region. Fixed effects of the model are: − 0.773 − 0.222 × mild/moderate ARDS + 0.984 × severe ARDS + 0.014 × time. All 
values are represented on the graph: circles for controls, triangles for mild/moderate ARDS patients, and squares for severe ARDS patients. b Mean 
gilz mRNA expression in neutrophils from ARDS patients with (n = 6) and without extracorporeal membrane oxygenation (n = 11). Results are 
expressed as the mean ± standard error of the mean gilz mRNA value. (*p < 0.05, Mann–Whitney test)
Page 9 of 12Espinasse et al. Ann. Intensive Care  (2016) 6:105 
only by anti-inflammatory signals such as glucocorticoids 
(GCs), but also by the inflammatory context as previously 
hypothesized in arthritis [13].
We recently demonstrated that the induction of neu-
trophil gilz expression promotes apoptosis [17]. Moreo-
ver, the combination of GCs and hypoxia has also been 
recently reported to induce neutrophil apoptosis in vitro 
[47]. Taken together, we could postulate that the induc-
tion of neutrophil gilz expression by GCs, hypoxia, and/
or other inflammatory signals could contribute to neu-
trophil apoptosis, necessary for lung repair.
Neutrophil gilz expression may thus help to resolve 
inflammation. There is growing interest in the possible 
role of two GC-induced proteins (Annexin A1 and GILZ) 
in the anti-inflammatory effects of GCs in vivo. Annexin 
A1 is upregulated during natural resolution of acute 
inflammation and has been shown to have pro-resolving 
and immunosuppressive properties both in vitro [48, 49] 
and in  vivo at the site of inflammation [18]. It was also 
recently demonstrated that Annexin A1 can control GILZ 
expression [19], revealing close cooperation between the 
two proteins in the resolution of inflammation. Here, 
we found that blood neutrophil annexin A1 mRNA lev-
els were not linked to ARDS severity, suggesting that 
annexin A1 is rather a general marker of inflammation 
resolution.
An anti-inflammatory role of endogenous GILZ in 
humans was first suggested by Beaulieu et  al. [13] in 
rheumatoid arthritis. More recently, Vago et  al. [18] 
demonstrated that GILZ administration accelerated and 
improved resolution of inflammation in a mouse model 
of acute lung injury (ALI). Interestingly, in a mouse 
model of LPS-induced ALI, we have found that GILZ is 
expressed in alveolar neutrophils and peaks when pulmo-
nary inflammation is maximal (Espinasse et  al., unpub-
lished observations). GILZ might thus participate in the 
regulation of inflammation in vivo.
This prospective observational pilot study has sev-
eral limitations. First, we had no access to alveolar neu-
trophils. Second, the cohort size was modest and not 
Fig. 5 CRP, extracellular DNA and annexin A1 mRNA levels in relation to ARDS severity. CRP (a), extracellular DNA (b), and annexin A1 mRNA (c) 
levels predicted by a linear mixed model. controls (full line), mild/moderate ARDS patients (small dotted line), and severe ARDS patients (large dot-
ted line) are represented. For each prediction, the confidence interval is represented by the gray region. All values are represented on the graph: 
circles for controls, triangles for mild/moderate ARDS patients, and squares for severe ARDS patients. Fixed effects of the model with the CRP are: 
5.314 − 0.175 × mild/moderate ARDS − 0.291 × severe ARDS − 0.036 × time. Fixed effects of the model with DNA are: 5.969 − 1.311 × mild/
moderate ARDS + 0.167 × severe ARDS − 0.011 × time. Fixed effects of the model with annexin A1 are: 0.400 − 0.125 × mild/moderate 
ARDS − 0.077 × severe ARDS + 0.003 × time
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sufficiently large for biomarker exploration. Third, we did 
not perform a power analysis because no reference data 
are available in this setting. Finally, because blood sam-
ples were obtained prospectively during usual care of 
patients until death or extubation, the number of samples 
is different for each patient and some patients may have 
a longer follow-up than others. This data attrition can be 
viewed as a missing data issue, and mixed effect modeling 
that we used in this study has been found robust in this 
setting [50], as they implicitly impute outcome trajecto-
ries beyond the time of death or extubation. More com-
plex modeling techniques could have been considered in 
this situation [51], but they were not applicable because 
of the relatively small sample size of this pilot study.
Conclusions
We show for the first time that GILZ, a potent regula-
tor of inflammation and an inducer of apoptosis, can be 
expressed by blood neutrophils of ARDS patients at both 
the gene and protein level. GILZ expression was tran-
sient and could occur without steroid therapy. Interest-
ingly, the highest neutrophil gilz expression levels were 
observed in patients with severe ARDS, and these levels 
correlated with the PaO2/FiO2 ratio; neutrophil GILZ 
may prove to be a potential biomarker for ARDS sever-
ity in a larger study. These data also suggest that blood 
neutrophil activation during ARDS might not only con-
tribute to lung injury but also participate in endogenous 
inflammation regulation.
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